China's Sinovac Vaccine 50.7% Effective Against Symptomatic COVID-19 Cases

China's Sinovac Vaccine 50.7% Effective Against Symptomatic COVID-19 Cases

April 13, 2021, 8:16 a.m.

CoronaVac, an inactivated COVID-19 vaccine developed by China's Sinovac Biotech Ltd., was shown to be 50.7% effective against symptomatic COVID-19 cases, according to new trial results revealed by Brazil's state-run Butantan Institute on Sunday.

The jab was also found to be equally effective against the two coronavirus variants known as P.1 and P.2, which were populated in Brazilian cities including Manaus and Rio de Janeiro.

The study, which the institute said had been sent to the medical journal The Lancet for publication, tested 12,400 volunteers across Brazil.

Malaysia said on Monday that it will begin vaccinating its elderly population with China's Sinovac jab starting next Monday, when phase two of its national immunization program starts.

More on Health

The Latest

Latest Magazine

VOL. 15, No. 08, Nov. 19, 2021 (Mangshir 03, 2078) Publisher and Editor: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 15, No. 07, Oct. 29, 2021 (Kartik 12, 2078) Publisher and Editor: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 15, No. 06, Oct. 08, 2021 (Ashoj 22, 2078) Publisher and Editor: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 15, No. 05, Sep. 17, 2021 (Ashoj 01, 2078) Publisher and Editor: Keshab Prasad Poudel Online Register Number: DOI 584/074-75